| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 257,237 | 65,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 956 | 805 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 147,324 | -19,301 |
| Cash and cash equivalents at beginning of period | 78,837 | - |
| Cash and cash equivalents at end of period | 226,161 | - |
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)